靶向脂质体药物传输市场规模、份额和增长分析（按产品、技术、适应症、最终用户和地区）- 2025 年至 2032 年行业预测

2023 年标靶脂质体药物传递市场规模价值 15.5 亿美元，预计将从 2024 年的 16.2 亿美元成长到 2032 年的 23 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.5%。

由于药物传输技术的进步，实现了特异性和可控的药物释放，从而最大限度地减少副作用并提高治疗效果，靶向脂质体药物传输市场预计将实现显着增长。慢性病盛行率的上升和对个人化医疗的需求的增加进一步推动了市场扩张。正在进行的研究、策略伙伴关係和增加的医疗保健投资也做出了贡献。目前，北美和欧洲凭藉其强大的医疗保健基础设施占据市场主导地位，而亚太地区则因注重医疗保健创新和不断扩大的患者群而提供了光明的机会。主要趋势包括开发新配方和寻找标靶治疗，凸显了该领域的动态和快速发展。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

标靶脂质体药物传递市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 脂质体紫杉醇
• 脂质体阿霉素
• 脂质体Amphotericin B
• 其他的

标靶脂质体药物传递市场规模（依技术及复合年增长率） (2025-2032)

• 市场概况
• 隐形脂质体技术
• 非聚乙二醇化脂质体技术
• Depoform 脂质体技术

标靶脂质体药物传递市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 真菌疾病
• 疼痛管理
• 抗癌药物
• 其他的

标靶脂质体药物传递市场规模（按最终用户和复合年增长率划分）（2025-2032 年）

• 市场概况
• 医院
• 诊所
• 研究部门
• 其他的

标靶脂质体药物传递市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Gilead Sciences, Inc.（United States）
• Pacira BioSciences, Inc.（United States）
• Spectrum Pharmaceuticals, Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Johnson & Johnson Services, Inc.（United States）
• Ipsen Pharma（France）
• Celsion Corporation（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Acrotech Biopharma, Inc.（United States）
• Astellas Pharma Inc.（Japan）
• Alnylam Pharmaceuticals, Inc.（United States）
• Arbutus Biopharma Corporation（Canada）
• Camurus AB（Sweden）
• Acuitas Therapeutics（Canada）

结论和建议

Targeted Liposomes Drug Delivery Market size was valued at USD 1.55 billion in 2023 and is poised to grow from USD 1.62 billion in 2024 to USD 2.3 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The Targeted Liposomes Drug Delivery Market is poised for significant growth, driven by advancements in drug delivery technologies that enable specific and controlled drug release, thereby minimizing side effects and enhancing therapeutic effectiveness. The rising prevalence of chronic diseases and a growing appetite for personalized medicine further fuel this market expansion. Continued research, strategic partnerships, and increased healthcare investments are also contributing factors. North America and Europe currently dominate the market due to robust healthcare infrastructure, while the Asia-Pacific region offers promising opportunities with its focus on healthcare innovation and expanding patient demographics. Key trends include the development of novel formulations and the exploration of targeted therapies, highlighting a dynamic and rapidly evolving landscape in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Targeted Liposomes Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Targeted Liposomes Drug Delivery Market Segments Analysis

Global Targeted Liposomes Drug Delivery Market is segmented by Product, Technology, Indication, End User and region. Based on Product, the market is segmented into Liposomal Paclitaxel, Liposomal Doxorubicin, Liposomal Amphotericin B and Others. Based on Technology, the market is segmented into Stealth Liposome Technology, Non-PEGylated Liposome Technology and DepoFoam Liposome Technology. Based on Indication, the market is segmented into Fungal Diseases, Pain Management, Cancer Therapeutics and Others. Based on End User, the market is segmented into Hospitals, Clinics, Research Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Targeted Liposomes Drug Delivery Market

The increasing demand for personalized and precision medicine significantly propels the growth of the targeted liposomes drug delivery market. Targeted liposomes serve as advanced delivery vehicles, providing controlled release and reducing side effects, ultimately enhancing therapeutic effectiveness. Additionally, the rising prevalence of chronic diseases, particularly cancer, has heightened interest in innovative drug delivery technologies such as targeted liposomes. This trend underscores the importance of these specialized systems in developing more efficient and tailored treatment options, reflecting a broader shift towards more individualized healthcare solutions aimed at improving patient outcomes and optimizing therapeutic interventions.

Restraints in the Targeted Liposomes Drug Delivery Market

A significant restraint facing the Targeted Liposomes Drug Delivery market is the high cost associated with advanced liposomal formulations and technologies, which can limit accessibility for some stakeholders. Additionally, the regulatory landscape presents challenges, with varying approval processes across different regions, potentially leading to delays in bringing new liposomal products to market. These barriers not only hinder innovation but also restrict the ability to capitalize on the therapeutic benefits that targeted liposome delivery systems could offer, ultimately affecting the overall growth and development of the market. Consequently, these factors pose hurdles for stakeholders aiming to invest and participate in this sector.

Market Trends of the Targeted Liposomes Drug Delivery Market

The Targeted Liposomes Drug Delivery market is witnessing a notable trend driven by the increasing emphasis on personalized medicine. As healthcare shifts toward individualized treatment approaches, there is a growing demand for customized liposomal formulations tailored to meet the specific needs of patients. Innovations in liposomal technology, including the development of smart and stimuli-responsive liposomes, are enhancing the precision of drug delivery. These advancements not only improve therapeutic efficacy but also minimize side effects, positioning targeted liposomes as a pivotal component in the future of personalized therapeutics. This focus on customization is likely to propel market growth and stimulate further research in the sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Liposomes Drug Delivery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Liposomal Paclitaxel
• Liposomal Doxorubicin
• Liposomal Amphotericin B
• Others

Global Targeted Liposomes Drug Delivery Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Stealth Liposome Technology
• Non-PEGylated Liposome Technology
• DepoFoam Liposome Technology

Global Targeted Liposomes Drug Delivery Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Fungal Diseases
• Pain Management
• Cancer Therapeutics
• Others

Global Targeted Liposomes Drug Delivery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Laboratories
• Others

Global Targeted Liposomes Drug Delivery Market Size & CAGR (2025-2032)

• North America (Product, Technology, Indication, End User)
  • US
  • Canada
• Europe (Product, Technology, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacira BioSciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celsion Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acrotech Biopharma, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Camurus AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acuitas Therapeutics (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations